

Report MQ 2026/1 Microbiology: Antibody and antigen tests

31.03.2026 V1.0

Summary

Sample		Results	Good	% Good
B01	Strep A Antigen	1269	1237	97.48 %
B04	Rubella / Mumps IgG/IgM	88	88	100.00 %
B05	Toxoplasmosis IgG/IgM	50	50	100.00 %
B06	Lues / syphilis serology	94	86	91.49 %
B07	Cytomegalovirus IgG/IgM	73	73	100.00 %
B08	Varicella / HSV1/2 IgG/IgM	113	112	99.12 %
B20	Epstein-Barr-Virus IgG/IgM	172	161	93.60 %
B21	Legionella antigen urine	75	75	100.00 %
B22	S. pneumoniae antigen urine	64	64	100.00 %
B24	RSV/Influenza rapid test	36	34	94.44 %
B27	Helicobacter Pylori Antigen	67	64	95.52 %
B30	Rota-/Adeno-/Norovirus Ag	78	78	100.00 %
B32	SARS-CoV-2 IgG/IgM	9	9	100.00 %
B33	SARS-CoV-2 Ag	31	29	93.55 %
B34	FSME IgG/IgM	12	12	100.00 %
B35	Measles/Parvovirus IgG/IgM	51	51	100.00 %
B37	C. Diff Ag (GDH, Toxin A/B)	80	80	100.00 %
B38	H. pylori Urease-Test	6	6	100.00 %
B39	Mycobacteria, microscopy	49	49	100.00 %
B42	HIV, Hepatitis B/C, serology	645	641	99.38 %
B43	Hepatitis A IgG / IgM	64	64	100.00 %
B44	Hepatitis E IgG / IgM	22	22	100.00 %
H11	Malaria rapid test / NAT	103	103	100.00 %
V01	HIV Rapid Test	30	30	100.00 %
Total		3281	3218	98.08 %

B01 Strep A Antigen

Strep A	Target Value	negative	positive	% Conform
Rapid Test	positive	32	1234	97.47
Abbott	positive	0	3	100.00
Total		32	1237	97.48

Commentary

The simulated liquid sample contained ipyogenes. The correct result was "Strep-A positive".

B04 Rubella / Mumps IgG/IgM

Mumps IgG	Target Value	negative	positive	% Conform
all Participants	positive	0	14	100.00

Mumps IgM	Target Value	negative	positive	% Conform
all Participants	negative	9	0	100.00

Rubella IgG	Target Value	negative	positive	% Conform
all Participants	positive	0	37	100.00

Rubella IgM	Target Value	negative	positive	% Conform
all Participants	negative	28	0	100.00

B05 Toxoplasmosis IgG/IgM

Toxo IgG avidity interpretation	Target Value	negative	positive	% Conform
all Participants	negative	1	0	100.00

Toxoplasma IgG	Target Value	negative	positive	% Conform
Abbott	negative	5	0	100.00
Roche	negative	11	0	100.00
Other methods	negative	9	0	100.00
Total		25	0	100.00

Toxoplasma IgM	Target Value	negative	positive	% Conform
Abbott	negative	5	0	100.00
Roche	negative	11	0	100.00
Other methods	negative	8	0	100.00
Total		24	0	100.00

B06 Lues / syphilis serology

Treponema TPHA	Target Value	negative	border	positive	% Conform
all Participants	positive	0	0	10	100.00

Treponema Screening (Ig total)	Target Value	negative	border	positive	% Conform
all Participants	positive	0	0	26	100.00

Treponema IgG	Target Value	negative	border	positive	% Conform
Immunoblot	positive	1	0	1	50.00
EIA	positive	0	0	10	100.00
Total		1	0	11	91.67

Treponema IgM	Target Value	negative	border	positive	% Conform
EIA	Borderline/pos	1	2	3	83.33
Immunoblot	positive	3	0	1	25.00
Total		4	2	4	60.00

RPR/VDRL	Target Value	negative	border	positive	% Conform
all Participants	positive	1	1	19	90.48

Syphilis TPPA	Target Value	negative	border	positive	% Conform
all Participants	positive	1	0	14	93.33

Commentary

The serum was obtained from a patient with active syphilis, who had high RPR/VDRL and TPHA titres, as well as a positive IgM result. This combination is typically consistent with Lues II, Lues III or latent syphilis. The IgM antibodies were detected using two independent methods; therefore, we have included the analysis in our assessment despite some negative results.

B07 Cytomegalovirus IgG/IgM

CMV IgG avidity interpretation	Target Value	negative	positive	% Conform
all Participants	positive	0	1	100.00

Cytomegaly IgG	Target Value	negative	positive	% Conform
Abbott	positive	0	6	100.00
Roche	positive	0	17	100.00
Other methods	positive	0	15	100.00
Total		0	38	100.00

Cytomegaly IgM	Target Value	negative	positive	% Conform
Abbott	negative	5	0	100.00
Roche	negative	16	0	100.00
Other methods	negative	13	0	100.00
Total		34	0	100.00

B08 Varicella / HSV1/2 IgG/IgM

HSV 1/2 IgG	Target Value	negative	positive	% Conform
all Participants	positive	0	5	100.00

HSV1 IgG	Target Value	negative	positive	% Conform
all Participants	positive	0	16	100.00

HSV1/2 IgM	Target Value	negative	positive	% Conform
all Participants	negative	19	0	100.00

HSV2 IgG	Target Value	negative	positive	% Conform
all Participants	negative	15	1	93.75

Varicella IgG	Target Value	negative	positive	% Conform
all Participants	positive	0	35	100.00

Varicella IgM	Target Value	negative	positive	% Conform
all Participants	negative	22	0	100.00

B20 Epstein-Barr-Virus IgG/IgM

EBV EBNA-1 IgG	Target Value	negative	border	positive	% Conform
Roche	positive	0	0	8	100.00
Abbott	positive	0	0	3	100.00
VIDAS	Borderline/pos	0	2	4	100.00
Liaison	Borderline/pos	4	2	4	60.00
Other methods	positive	1	0	5	83.33
Total		5	4	24	72.73

EBV heterophilic antibodies	Target Value	negative	border	positive	% Conform
Rapid Test	negative	69	0	3	95.83

EBV VCA-IgG	Target Value	negative	border	positive	% Conform
Roche	positive	0	0	9	100.00
Abbott	Borderline/pos	0	1	2	100.00
VIDAS	negative	6	0	0	100.00
Liaison	Borderline/neg	8	1	1	90.00
Other methods	negative	4	0	2	66.67
Total		18	2	14	41.18

EBV VCA-IgM	Target Value	negative	border	positive	% Conform
Roche	negative	8	0	0	100.00
Abbott	negative	3	0	0	100.00
VIDAS	negative	6	0	0	100.00
Liaison	negative	10	0	0	100.00
Other methods	negative	6	0	0	100.00
Total		33	0	0	100.00

Commentary

The serum came from a member of staff who had suffered from an EBV infection some time ago. We have identified methodological differences regarding VCA-IgG. For this reason, the reference ranges for EBV VCA-IgG vary depending on the method used.

B21 Legionella antigen urine

Legionella antigen urine	Target Value	negative	positive	% Conform
Quidel Sofia	positive	0	18	100.00
BinaxNOW	positive	0	34	100.00
Other methods	positive	0	23	100.00
Total		0	75	100.00

B22 S. pneumoniae antigen urine

S. pneumoniae antigen urine	Target Value	negative	positive	% Conform
BinaxNOW	negative	27	0	100.00
Quidel Sofia	negative	15	0	100.00
Other methods	negative	22	0	100.00
Total		64	0	100.00

B24 RSV/Influenza rapid test

Influenza A Antigen	Target Value	negative	border	positive	% Conform
all Participants	negative	3	0	0	100.00

Influenza B Antigen	Target Value	negative	border	positive	% Conform
all Participants	positive	0	0	3	100.00

Influenza Ag	Target Value	negative	border	positive	% Conform
Quidel Sofia	positive	0	0	1	100.00
Other methods	positive	1	1	8	80.00
Total		1	1	9	81.82

RSV Antigen	Target Value	negative	border	positive	% Conform
BinaxNOW	negative	2	0	0	100.00
Other methods	negative	17	0	0	100.00
Total		19	0	0	100.00

B27 Helicobacter Pylori Antigen

Helicobacter pylori antigen	Target Value	negative	positive	% Conform
CerTest Biotec	positive	1	12	92.31
Liaison	positive	0	13	100.00
Meridian STAT! HpSA	positive	0	5	100.00
Oxoid RAPID Hp StAR	positive	1	4	80.00
Ridascreen	positive	0	7	100.00
SD-Biosensor	positive	0	6	100.00
Rapid Test	positive	1	17	94.44
Total		3	64	95.52

B30 Rota-/Adeno-/Norovirus Ag

Adenovirus Ag	Target Value	negative	positive	% Conform
CerTest Biotec	positive	0	8	100.00
r-biopharm	positive	0	6	100.00
SD-Biosensor	positive	0	6	100.00
Other methods	positive	0	15	100.00
Total		0	35	100.00

Norovirus Ag	Target Value	negative	positive	% Conform
all Participants	negative	10	0	100.00

Rotavirus Ag	Target Value	negative	positive	% Conform
CerTest Biotec	negative	9	0	100.00
r-biopharm	negative	6	0	100.00
SD-Biosensor	negative	6	0	100.00
Other methods	negative	12	0	100.00
Total		33	0	100.00

B32 SARS-CoV-2 IgG/IgM

SARS-CoV-2 IgG	Target Value	negative	positive	% Conform
all Participants	positive	0	1	100.00

SARS-CoV-2 IgG NCP	Target Value	negative	positive	% Conform
Roche	positive	0	1	100.00
all Participants	positive	0	1	100.00
Total		0	2	100.00

SARS-CoV-2 IgG Spike 1	Target Value	negative	positive	% Conform
all Participants	positive	0	4	100.00

SARS-CoV-2 IgG Spike 2 Ak	Target Value	negative	positive	% Conform
all Participants	positive	0	1	100.00

SARS-CoV-2 IgG/A/M	Target Value	negative	positive	% Conform
Roche	positive	0	1	100.00

B33 SARS-CoV-2 Ag

SARS-CoV-2 Antigen	Target Value	negative	positive	% Conform
Roche	positive	0	9	100.00
Other methods	positive	2	20	90.91
Total		2	29	93.55

B34 FSME IgG/IgM

FSME IgG	Target Value	negative	positive	% Conform
all Participants	negative	6	0	100.00

FSME IgM	Target Value	negative	positive	% Conform
all Participants	negative	6	0	100.00

B35 Measles/Parvovirus IgG/IgM

Masern IgG	Target Value	negative	positive	% Conform
all Participants	positive	0	14	100.00

Masern IgM	Target Value	negative	positive	% Conform
all Participants	negative	10	0	100.00

Parvovirus B19 IgG	Target Value	negative	positive	% Conform
all Participants	negative	14	0	100.00

Parvovirus B19 IgM	Target Value	negative	positive	% Conform
all Participants	negative	13	0	100.00

B37 C. Diff Ag (GDH, Toxin A/B)

C. Diff GDH	Target Value	negative	positive	% Conform
Ridascreen	positive	0	8	100.00
Techlab C.Diff Quick Chek	positive	0	14	100.00
Other methods	positive	0	15	100.00
Total		0	37	100.00

C. Diff Toxin A	Target Value	negative	positive	% Conform
all Participants	positive	0	7	100.00

C. Diff Toxin B	Target Value	negative	positive	% Conform
all Participants	negative	7	0	100.00

C. Diff Tox A/B	Target Value	negative	positive	% Conform
Ridascreen	positive	0	9	100.00
Techlab C.Diff Quick Chek	positive	0	13	100.00
Other methods	positive	0	7	100.00
Total		0	29	100.00

B38 H. pylori Urease-Test

H. pylori Urease-Test	Target Value	negative	positive	% Conform
Rapid Test	positive	0	6	100.00

B39 Mycobacteria, microscopy

Acid-fast bacilli A	Target Value	negative	positive	% Conform
Ziehl-Neelsen	negative	20	0	100.00
Auramin-Rhodamin	negative	4	0	100.00
Total		24	0	100.00

Acid-fast bacilli B	Target Value	negative	positive	% Conform
Auramin-Rhodamin	positive	0	4	100.00
Ziehl-Neelsen	positive	0	21	100.00
Total		0	25	100.00

B42 HIV, Hepatitis B/C, serology

HBs Ag sample A	Target Value	negative	positive	% Conform
Abbott	positive	0	12	100.00
Roche	positive	0	31	100.00
Other methods	positive	1	13	92.86
Total		1	56	98.25

Anti-HBs Ig total sample A	Target Value	negative	positive	% Conform
Abbott	negative	8	0	100.00
Roche	negative	28	0	100.00
Other methods	negative	8	0	100.00
Total		44	0	100.00

Anti-HBc Ig total sample A	Target Value	negative	positive	% Conform
Abbott	positive	0	9	100.00
Roche	positive	0	31	100.00
Other methods	positive	0	8	100.00
Total		0	48	100.00

Anti-HBc IgM sample A	Target Value	negative	positive	% Conform
Abbott	negative	6	0	100.00
Roche	negative	8	0	100.00
Other methods	negative	3	0	100.00
Total		17	0	100.00

HBe Ag sample A	Target Value	negative	positive	% Conform
Abbott	negative	7	0	100.00
Roche	negative	7	0	100.00
Other methods	negative	4	0	100.00
Total		18	0	100.00

Anti-HBe Ig total sample A	Target Value	negative	positive	% Conform
Abbott	positive	0	6	100.00
Roche	positive	0	7	100.00
Other methods	positive	0	4	100.00
Total		0	17	100.00

Anti-HCV Ig total sample A	Target Value	negative	positive	% Conform
Abbott	negative	12	0	100.00
Roche	negative	29	0	100.00
Other methods	negative	15	0	100.00
Total		56	0	100.00

HIV 1/2 Combo sample A	Target Value	negative	positive	% Conform
Abbott	negative	12	0	100.00
Roche	negative	37	0	100.00
Other methods	negative	14	0	100.00
Total		63	0	100.00

HBs Ag sample B	Target Value	negative	positive	% Conform
Abbott	negative	12	0	100.00
Roche	negative	31	0	100.00
Other methods	negative	13	1	92.86
Total		56	1	98.25

Anti-HBs Ig total sample B	Target Value	negative	positive	% Conform
Abbott	positive	0	8	100.00
Roche	positive	0	29	100.00
Other methods	positive	0	8	100.00
Total		0	45	100.00

Anti-HBc Ig total sample B	Target Value	negative	positive	% Conform
Abbott	negative	9	0	100.00
Roche	negative	31	0	100.00
Other methods	negative	8	0	100.00
Total		48	0	100.00

Anti-HBc IgM sample B	Target Value	negative	positive	% Conform
Abbott	negative	6	0	100.00
Roche	negative	10	0	100.00
Other methods	negative	3	0	100.00
Total		19	0	100.00

HBe Ag sample B	Target Value	negative	positive	% Conform
Abbott	negative	7	0	100.00
Roche	negative	7	0	100.00
Other methods	negative	4	0	100.00
Total		18	0	100.00

Anti-HBe Ig total sample B	Target Value	negative	positive	% Conform
Abbott	negative	5	1	83.33
Roche	negative	7	0	100.00
Other methods	negative	4	0	100.00
Total		16	1	94.12

Anti-HCV Ig total sample B	Target Value	negative	positive	% Conform
Abbott	negative	12	0	100.00
Roche	negative	29	0	100.00
Other methods	negative	15	0	100.00
Total		56	0	100.00

HIV 1/2 Combo sample B	Target Value	negative	positive	% Conform
Abbott	positive	0	12	100.00
Roche	positive	0	37	100.00
Other methods	positive	1	15	93.75
Total		1	64	98.46

B43 Hepatitis A IgG / IgM

Anti-HAV Ig	Target Value	negative	positive	% Conform
Roche	negative	18	0	100.00
Other methods	negative	8	0	100.00
Total		26	0	100.00

Anti-HAV IgG	Target Value	negative	positive	% Conform
Abbott	negative	6	0	100.00
all Participants	negative	1	0	100.00
Total		7	0	100.00

Anti-HAV IgM	Target Value	negative	positive	% Conform
Abbott	negative	6	0	100.00
Roche	negative	16	0	100.00
Other methods	negative	9	0	100.00
Total		31	0	100.00

B44 Hepatitis E IgG / IgM

Anti-HEV IgG	Target Value	negative	positive	% Conform
all Participants	positive	0	11	100.00

Anti-HEV IgM	Target Value	negative	positive	% Conform
all Participants	positive	0	11	100.00

H11 Malaria rapid test / NAT

Malaria	Target Value	negative	positive	% Conform
Paramax	positive	0	9	100.00
BinaxNOW	positive	0	43	100.00
SD-Biosensor	positive	0	33	100.00
NAT Amp.	positive	0	6	100.00
Other methods	positive	0	8	100.00
Total		0	99	100.00

Plasmodium spp.	Target Value	negative	positive	% Conform
Biofire/Filmarray	positive	0	2	100.00

Plasmodium falciparum	Target Value	negative	positive	% Conform
Biofire/Filmarray	positive	0	2	100.00

Commentary

The sample contained *P. falciparum*.

V01 HIV Rapid Test

HIV Rapid Test	Target Value	negative	positive	% Conform
Determine HIV 1/2	negative	25	0	100.00
Other methods	negative	5	0	100.00
Total		30	0	100.00
